Vertex Pharma (VRTX) Offering Possible 19.05% Return Over the Next 10 Calendar Days

This article was originally published on this site

Vertex Pharma’s most recent trend suggests a bearish bias. One trading opportunity on Vertex Pharma is a Bear Call Spread using a strike $157.50 short call and a strike $162.50 long call offers a potential 19.05% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $157.50 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $4.20 would be incurred if the stock rose above the $162.50 long call strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Vertex Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Vertex Pharma is bullish.

The RSI indicator is at 69.61 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Vertex Pharma

Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings
Sat, 05 Aug 2017 00:01:00 +0000
Vertex Pharmaceuticals and Regeneron Pharmaceuticals are enjoying rapid sales and profit growth this year. Did one of them execute on their strategy better than the other last quarter?

Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
Thu, 03 Aug 2017 23:45:00 +0000
The company reported mid-stage trial data that suggests it may be able to treat even more cystic fibrosis patients someday.

Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons
Thu, 03 Aug 2017 13:46:02 +0000
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has shined bright within the biotech industry this year. VRTX stock has more than doubled over the past 12 months. Then the company added more fuel to the fire last month, with new drug data results coming in favorably.

Corporate News Blog – Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis
Thu, 03 Aug 2017 11:10:00 +0000
Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 3, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for …

Vertex’s latest FDA nod could boost sales by $150M: analyst
Wed, 02 Aug 2017 16:35:08 +0000
Vertex Pharmaceuticals could see its annual revenue increase by more than $150 million following an FDA decision on Tuesday that will allow hundreds of new patients to use its cystic fibrosis drug Kalydeco, according to one analyst. The FDA initially approved Kalydeco in 2012 for cystic fibrosis patients with one specific type of genetic mutation that causes the lung disease, but it has since gradually expanded the approval to cover additional patients. The latest boost came on Tuesday, when Vertex (VRTX) said that the FDA had approved Kalydeco for use in more than 600 patients who have any of five different mutations.

Be Sociable, Share!

Related Posts